1. Netweb Technologies India: 

ICICI Securities maintains its ‘Buy’ rating on this IT company, with a price of Rs 5,360, an upside of 12.6%. The company’s Q1FY27 net profit rose 20.9% QoQ, while revenue grew 5.9%. Faster delivery of orders for AI systems, high-performance computing, and private cloud platforms drove this growth.

The company benefits from India's rising investments in AI infrastructure. During the quarter, Netweb completed orders worth Rs 430 crore under the government’s IndiaAI Mission. Management forecasts demand to remain strong over the next two years. Analysts Seema Nayak and Ruchi Mukhija note that the company is expanding into high-growth areas, including digital replicas of machines, AI-powered physical systems and quantum computing.

Netweb’s potential order pipeline exceeds Rs 10,400 crore, a 151% YoY increase. Management anticipates converting about 60% of these prospects into firm orders, offering clear revenue visibility.

Nayak and Mukhija expect Netweb to outpace the broader IT industry, fueled by rising AI adoption and government digital spending. They project revenue to nearly double in FY27 while the company maintains healthy profit margins.

2. Radico Khaitan: 

ICICI Direct maintains its ‘Buy’ rating on this liquor maker, with a target price of Rs 5,100, an upside of 14.6%. Analysts Kaustubh Pawaskar and Abhishek Shankar remain optimistic after a strong Q1FY27 performance. Ramp-up of the premium and luxury liquor portfolio boosted revenue by 11.8% YoY, while net profit jumped 75.9% on premiumisation.

The premium and above (P&A) segment led this performance with a 36% volume increase, driven by record quarterly sales of Magic Moments Vodka. Consequently, management raised its FY27 P&A volume growth guidance from 20% to 25%. The company aims to clear its net debt by Q2, as it plans no major expansion capital expenditure and will focus only on routine maintenance.

Pawaskar and Shankar expect premium brands to continue driving growth and improving profit margins. They forecast EBITDA margin to reach approximately 21% by FY28 through cost controls and better factory utilisation. Eliminating debt will also allow Radico to return capital to shareholders or fund future acquisitions.

3. Indegene: 

IDBI Capital initiates coverage on this healthcare services provider with a ‘Buy’ rating and a target price of Rs 620, implying an upside of 12%. The company reported mixed Q1FY27 results, as revenue rose 39.5% YoY, driven by demand for life sciences commercialisation, medical affairs, and enterprise services. However, rising staff and finance costs kept net profit flat at Rs 116.2 crore.

Analysts Saptarshi Mukherjee and Darshan Bhutra believe that rising drug development costs, patent expiries, and increased outsourcing by pharmaceutical companies will drive long-term revenue growth. Indegene expanded its client base beyond its top 20 accounts, doubling its mid-sized and emerging biotech clients to 53. This diversification reduces client concentration risk and taps into innovative biopharma firms that lack in-house marketing setups.

Mukherjee and Bhutra note that as the only listed, pure-play life sciences commercialisation specialist in India, Indegene commands a unique market position. They project both revenue and net profit to grow at a CAGR of about 18% through FY28, supported by improving margins, strong cash generation, and competitive advantages in pharmaceutical outsourcing.

4. PN Gadgil Jewellers: 

Motilal Oswal reiterates its ‘Buy’ rating on this jewellery retailer, with a target price of Rs 825, implying a 26.1% upside. The retailer delivered robust Q1FY27 results, as revenue grew 41% YoY on higher retail and same-store sales. Customer footfall rose, with a high 92% conversion rate.

Analysts Naveen Trivedi and Amey Tiwari project strong revenue growth in FY27, citing healthy consumer demand, a greater share of studded jewellery, and solid brand equity. Management plans to expand through franchise stores and a focused regional strategy. Because wedding demand shifted to later quarters, the company has a clear path to open 25 new stores in H2FY27.

Trivedi and Tiwari expect profit margins to remain steady. Increased proportion of studded jewellery and old-gold exchanges will help offset volatile gold prices. They add that cost controls, gold hedging, and expansion into Uttar Pradesh will improve operational efficiency. Analysts forecast revenue and net profit to grow at a CAGR of 19% and 20%, respectively, over FY27–28.

5. Coforge: 

Axis Direct maintains its ‘Buy’ rating on this IT services company, with a target price of Rs 2,275, an upside of 30%. In Q1FY27, revenue rose 24.2% QoQ, driven by steady deal execution and the successful integration of US-based AI firm Encora. Analysts Kuber Chauhan and Abhishek Bhalotia highlight that Coforge maintains the IT industry's lowest attrition rate at 10.4%.

Management remains confident about future growth, supported by a record 12-month executable order book of $2.2 billion, up 44% YoY. The company secured $691 million in orders during the quarter and expects more large deals in Q2. The Encora acquisition expands Coforge's footprint in healthcare and high-tech while opening new cross-selling paths.

Coforge reaffirmed its FY27 guidance, projecting an EBITDA margin of 20.5-21%. AI remains a priority, with teams using AI-led delivery models in over 30% of active projects. Chauhan and Bhalotia expect Coforge to outperform peers through strong execution and its expanding AI capabilities. They forecast annual revenue and net profit to grow by 32.1% and 41.5%, respectively, over FY27-28.

Note: These recommendations are from various analysts and are not recommendations by Trendlyne.

(You can find all analyst picks here)